A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

Trial Profile

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Glesatinib (Primary) ; Mocetinostat (Primary) ; Nivolumab (Primary) ; Sitravatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Mirati Therapeutics
  • Most Recent Events

    • 14 Sep 2017 According to a Mirati Therapeutics media release, preliminary efficacy and safety data from this trial will be presented at the IASLC 18th World Conference on Lung Cancer.
    • 06 Sep 2017 Data from this trial will be presented at the IASLC 18th World Conference on Lung Cancer, according to a Mirati Therapeutics media release.
    • 09 Mar 2017 According to a Mirati Therapeutics media release, the company expects to provide initial results from this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top